T1a RCC Death Risk Higher After Ablation vs Partial Nephrectomy
Study included a large, contemporary cohort of patients with T1a renal cell carcinoma undergoing partial nephrectomy or local tumor destruction.
Renal Cell Carcinoma
Follow-Up Confirms DFS Benefit With Pembrolizumab in Clear Cell RCC
Adjuvant pembrolizumab could be a new standard of care for patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, according to researchers.
Real-World Data Support Nivolumab + Ipilimumab for First-Line mRCC Therapy
Study revealed an objective response rate consistent with that observed in the CheckMate 214 clinical trial and a low rate of treatment-related adverse events.
Adjuvant Nivolumab-Ipilimumab Failed to Improve DFS in Renal Cell Carcinoma
Nivolumab plus ipilimumab did not prolong disease-free survival, and 43% of patients discontinued treatment due to toxicities.
COSMIC-313: Triplet Prolongs PFS vs Doublet in Renal Cell Carcinoma
The PFS benefit was driven primarily by patients with intermediate-risk disease.
Previous Cannabis Use Linked to Lower Risk of Some Genitourinary Cancers
A new study suggests that previous use of cannabis is associated with a lower risk of certain genitourinary cancers.
Normonatremia Tied to Outcomes in Metastatic Renal Cell Carcinoma
Serum sodium levels in the lower end of the normal range are associated with inferior outcomes in metastatic renal cell carcinoma, a study suggests.
Estimating Post-Nephrectomy GFR May Guide Treatment Decisions
An accurate estimate of future GFR after nephrectomy would help to guide operative strategy and use of adjuvant or neoadjuvant therapies, according to a recent editorial.
Immune Checkpoint Inhibitor Therapy Linked With Improved Quality of Life
Among patients with a variety of solid tumors, investigators found favorable associations of immune checkpoint inhibitor therapy with quality of life compared with no immunotherapy use.
Trial Evaluating Nivolumab Plus Ipilimumab for Localized RCC Misses Endpoint
The CheckMate -914 trial included patients with localized RCC who underwent radical or partial nephrectomy and who were at high risk of relapse.
- Loading...
Loading...
Next post in Kidney Cancer
Loading... 
Loading...